New Approach Methodologies

Effectiveness of NAMs in the medical field examined.

Tags:

nam
medicine

WHERNTO: wellnes erudite righton

This is a webpage compiled from comprehensive reports by Perplexity, Gemini, Mistral AIs, as well as a NAM summary by Dr. Zheng Tan on validated medical developments as of <2026-03-24 Tue>.

Preamble

The discovery items have been compiled and organized by Mistral AI into 7 themes:

AI-Driven Drug Discovery & Repurposing
Organ-on-a-Chip & Microphysiological Systems
Human Organoids & Organoid-Based Models
In Silico Modeling, PBPK, and Computational Methods
High-Throughput & Omics-Based Approaches
Toxicology & Safety Assessment via NAMs
Regulatory & Industry Adoption of NAMs

Each item is presented in a consistent format:
Discovery
Validation
Impact
References

A summary table and conclusion are provided at the end of this webpage.Please note that the term NAM is used to cover a wide range of items including those that can be said to be NAM-enabling.

Here are the AI reports:
NAM-gemini.pdf
NAM-mistral.pdf
NAM-perplexity.pdf

Here is the NAM summary document kindly created by Dr. Zheng Tan which contains additional insights for several items such as:
Development Team
Country
Significance of NAM discovery

The graphic was generated by Mistral and represents a microscopic view of organoid and NAM technology.

Introduction

New Approach Methodologies (NAMs) represent a paradigm shift in biomedical research and drug development, replacing or supplementing traditional animal testing with human-relevant, in vitro, in silico, and in chemico technologies. This report synthesizes peer-reviewed, validated medical discoveries enabled by NAMs, organized thematically to highlight their scientific, clinical, and regulatory impact.

1. AI-Driven Drug Discovery & Repurposing

Artificial Intelligence (AI) and machine learning (ML) are revolutionizing drug discovery by analyzing vast datasets to identify novel drug candidates, predict drug responses, and repurpose existing drugs for new therapeutic uses. This section highlights groundbreaking discoveries where AI-driven approaches have accelerated drug development timelines, reduced reliance on animal testing, and provided actionable insights for treating complex diseases such as COVID-19, idiopathic pulmonary fibrosis, and neurodegenerative disorders.

1.1 AI-Powered Drug Repurposing for COVID-19

Discovery: The JAK inhibitor baricitinib (originally approved for rheumatoid arthritis) was identified as a potential COVID-19 therapy using an AI-driven in silico NAM. The model predicted its ability to block SARS-CoV-2 infection and modulate cytokine signaling pathways.
Validation: Subsequent clinical trials confirmed that baricitinib, when added to standard care, reduced mortality and improved outcomes in hospitalized COVID-19 patients.
Impact: Demonstrated the power of AI-driven drug repurposing for pandemic response.
References: Can New Approach Methodologies De-Risk Drug Development?

1.2 AI-Designed Novel Drug Candidate for Idiopathic Pulmonary Fibrosis

Discovery: Insilico Medicine’s AI platform designed a novel drug candidate for idiopathic pulmonary fibrosis in just 18 months, integrating multimodal omics data (single-cell transcriptomics, proteomics) with deep generative models and graph neural networks.
Validation: The candidate advanced to Phase II clinical trials, showcasing AI’s ability to accelerate drug discovery timelines.
Impact: Reduced reliance on animal testing and shortened the drug development pipeline.
References: From AI-Assisted In Silico Computational Design to Preclinical In Vivo Models

1.3 Topiramate for Inflammatory Bowel Disease (IBD)

Discovery: Transcriptomic reversal scoring and network pharmacology identified topiramate as a candidate for IBD by predicting its ability to reverse disease-specific expression profiles.
Validation: Further preclinical and clinical studies are ongoing to validate its efficacy.
Impact: Demonstrated the potential of AI-driven repurposing for complex diseases.
References: From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases

1.4 Drug Repurposing for Neurodegenerative Disorders

Discovery: High-throughput screening (HTS) identified compounds capable of disrupting 14-3-3 protein interactions, offering potential treatments for Amyotrophic Lateral Sclerosis (ALS).
Validation: AI integrating advanced computational techniques is overcoming the limitations of conventional HTS which are primarily huge volume of compounds and bio-interaction complexities.
Impact: Provided new therapeutic avenues for neurodegenerative diseases with unmet medical needs.
References: AI-driven High Throughput Screening for Targeted Drug Discovery, How AI Contributes to make High-Throughput Screening more Efficient, [New Approach Methodologies Facilitating Drug Discovery](https://www.biotechniques.com/drug-discovery-development/if-sart-nams-an-e xciting-era-for-drug-discovery_sartorius/)

1.5 CoreFinder: AI-Driven Discovery of Biosynthetic Gene Clusters

Discovery: The CoreFinder system, a transformer-based model, predicted biosynthetic gene cluster (BGC) functions in fungi, uncovering novel BGCs validated through in vitro fermentation and LC-MS analysis.
Validation: Demonstrated the ability of AI to drive valid scientific discoveries independently of traditional experimental paradigms.
Impact: Unlocked new biosynthetic pathways for pharmaceutical advancement.
References: Deciphering Biosynthetic Gene Clusters with a Context-aware Protein Language Model

1.6 Disrupting TSLP Signaling as a Treatment for Atopic Diseases

Discovery: Identified putative small molecule inhibitors that disrupt TSLP–TSLP receptor interactions.
Validation: Demonstrated efficacy in human cell assays using in vitro human cell-based drug screening for atopic diseases (e.g., atopic dermatitis, asthma), leading to novel treatment options.
Impact: Provides a human-relevant alternative to animal models for drug discovery in inflammatory skin diseases.
References: Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases

2. Organ-on-a-Chip & Microphysiological Systems

Organ-on-a-chip and microphysiological systems replicate the dynamic, multi-cellular environments of human organs in microfluidic devices, enabling high-fidelity studies of drug effects, disease mechanisms, and toxicity. By mimicking tissue-tissue interfaces, fluid flow, and mechanical forces, these platforms offer human-relevant alternatives to traditional animal models, driving advances in personalized medicine and regulatory-approved drug development tools.

2.1 Emulate Liver-on-a-Chip Identifies Hepatotoxicity

Discovery: The Emulate liver-on-a-chip model correctly identified hepatotoxicity in 87% of drugs that had tested as safe in animal models but were later found toxic in humans (see Performance assessment link below).
Validation: The platform recapitulated human-specific metabolic dynamics, including albumin secretion and mechanical stimuli in the extracellular matrix.
Impact: Highlighted the superiority of human-relevant microphysiological systems over animal models for predicting drug-induced liver injury (DILI).
References: Tumor organoids for cancer research and personalized medicine, Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology, What are NAMs?

2.2 Acetaminophen (Tylenol) Toxicity Mechanism

Discovery: Liver-on-a-chip technology (see 2.1) equipped with nanotechnology-based optoelectronic sensors identified that acetaminophen blocks cellular respiration in minutes at much lower doses than previously believed, revealing an ultra‑rapid mitochondrial respiration impairment component not captured in legacy in vivo studies.
Validation: Sensors placed inside the bionic tissue detected rapid changes in oxygen uptake at much lower doses than previously believed from decades of animal research.
Impact: Provides a human-specific explanation for rare off-target effects and skin reactions that traditional animal models failed to capture, transforming safety protocols for one of the world’s most common medications.
References: Hepatotoxic assessment in a microphysiological system, What are NAMs?

2.3 Lung-on-a-Chip for Antiviral Efficacy

Discovery: A human lung-on-a-chip system (Emulate Bio) tested RNA-based antiviral therapies for influenza, showing significant reduction in viral replication and inflammatory responses with minimal off-target toxicity.
Validation: Demonstrated efficacy and safety under physiologically relevant conditions (air-liquid interface, dynamic flow).
Impact: Provided a human-relevant platform for antiviral drug testing, overcoming limitations of static cultures and animal models.
References: Lung-On-A-Chip Technologies for Disease Modeling and Drug Development, Human Lung-on-a-Chip Model Demonstrates Potential for Testing Preclinical Influenza Therapeutics, Revolutionizing respiratory health research

2.4 Lung-on-a-Chip for Tumor Heterogeneity & Drug Resistance

Discovery: Microfluidic lung-on-a-chip platforms modeled lung cancer microenvironments, enabling Label-free real-time classification of tumor cells at 10,000 cells/second as well as tracking of drug-resistant subpopulations (e.g., EGFR T790M mutations in non-small-cell lung cancer).
Validation: Demonstrated the ability to observe tumor heterogeneity and resistance dynamics in a human-relevant system.
Impact: Accelerated the development of targeted therapies and personalized treatment strategies.
References: Progress and application of lung-on-a-chip for lung cancer, The potential of lung-on-a-chip as an alternative to animal testing, Microfluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation

2.5 Liver and Skin Organ-on-a-Chip for PK-PD Studies

Discovery: The HUMIMIC Chip2 integrated liver spheroids and skin models to study pharmacokinetic-pharmacodynamic (PK-PD) relationships under chemical exposure.
Validation: Demonstrated the platform’s utility for quantifying drug metabolism and toxicity in a human-relevant, multi-organ context.
Impact: Supported regulatory acceptance of organ-on-a-chip technologies as drug development tools.
References: Organ-on-a-chip meets artificial intelligence in drug evaluation, Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation

2.6 ALS Pathogenesis and Early Biomarkers

Discovery: Human spinal cord organ-chips integrated with vascular interfaces modeled early sporadic Amyotrophic Lateral Sclerosis (ALS), uncovering neurofilament dysregulation and synaptic signaling defects.
Validation: Multi-omics analysis confirmed these molecular changes occur before overt neuron loss, mirroring clinical biomarkers that are difficult to detect in animal models.
Impact: Offers a human-relevant platform to study early disease progression and identify therapeutic targets before irreversible nerve damage occurs.
References: Organ-Chip ALS Model Uses Patient iPSCs to Uncover Early Disease Progression, An organ-chip model of sporadic ALS using iPSC

2.7 GABAergic Signaling in Cancer Invasion

Discovery: Patient-derived tumor organ-chips proved that tumor-derived GABA acts as a marker of poor prognosis and directly promotes invasion in metastatic colorectal cancer.
Validation: Interrogating the underlying biology on-chip demonstrated that inhibiting GABA synthesis significantly reduced invasive behavior, capturing patient-specific heterogeneity more faithfully than static cultures.
Impact: Establishes a new therapeutic target for colorectal cancer and validates the ability of organ-chips to replicate the complex tumor microenvironment.
References: GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

2.8 Cervical Protective Role in Dysbiosis

Discovery: Linked Cervix and Vagina Organ-Chips demonstrated that cervical mucus actively modulates vaginal inflammation and protects the epithelium from injury during dysbiosis.
Validation: Exposure to cervix-derived mucus on-chip reduced inflammatory responses and altered protein expression profiles, identifying potential new biomarkers for bacterial vaginosis.
Impact: Uncovers human-specific protective mechanisms that cannot be studied in animal models, facilitating the discovery of new feminine health therapeutics.
References: Cervical mucus in linked human Cervix and Vagina Chips modulates vaginal dysbiosis

2.9 Lung-on-a-Chip Replicates Human Lung Disease and Drug Responses

Discovery: Microfluidic chips lined with human lung cells modeled pulmonary edema, COPD, and drug toxicity.
Validation: Demonstrating superior predictive value over animal models for lung disease and toxicity, it is recognized by the FDA as a valid testing platform for specific drug submissions.
Impact: Enabled more accurate modeling of human lung responses to drugs and diseases.
References: Reconstituting Organ-Level Lung Functions on a Chip, A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice

2.10 Human Skin-Lymphoreticular Model-on-Chip for Inflammatory Skin Diseases

Discovery: Developed a human-based skin-lymphoreticular model-on-chip emulating inflammatory skin conditions capturing immune-skin interactions on a chip platform.
Validation: Demonstrated utility for studying atopic dermatitis and related diseases.
Impact: Eliminates the need for animal models in studying inflammatory skin diseases.
References: A Human‐Based Skin‐Lymphoreticular Model‐on‐Chip to Emulate Inflammatory Skin Conditions

3. Human Organoids & Organoid-Based Models

Human organoids are three-dimensional, self-organizing cultures derived from stem cells that recapitulate the structure and function of human organs. This section showcases how organoids are transforming disease modeling, drug screening, and gene therapy development, enabling precision medicine approaches for conditions like cystic fibrosis, Duchenne muscular dystrophy, and cancer.

3.1 Forskolin-Induced Swelling (FIS) Assay for Cystic Fibrosis

Discovery: Patient-derived intestinal organoids from Cystic Fibrosis (CF) patients were used in the Forskolin-induced Swelling (FIS) assay to test CFTR-modulator drugs.
Validation: The assay accurately predicted clinical trial responses for individual patients, including rare genotypes.
Impact: Enabled tailored therapeutic strategies, significantly increasing life expectancy for CF patients.
References: Towards diagnostic and personalized models using organoids, NAMs: an exciting era for drug discovery

3.2 Patient-Derived Organoids for Gene Therapy in Duchenne Muscular Dystrophy (DMD)

Discovery: A breakthrough workflow converted cryopreserved peripheral blood mononuclear cells (PBMCs) into induced pluripotent stem cells (iPSCs) and then into cardiac organoids within three weeks, correcting unique splicing defects in DMD patients.
Validation: Custom ASOs restored dystrophin expression and improved calcium transients in cardiac organoids.
Impact: Provided a scalable, cost-effective alternative to animal models for developing personalized gene therapies.
References: Patient-Derived Organoids for Gene Therapy Development

3.3 Patient-Derived Organoids for Metastatic Colorectal Cancer (OPTIC Trial)

Discovery: The OPTIC trial validated the predictive power of patient-derived organoids (PDOs) for metastatic colorectal cancer (mCRC) and the PDO response correlated with radiological tumor response and clinical survival outcomes, particularly for oxaliplatin-based chemotherapy.
Validation: Demonstrated 83.3% accuracy in predicting patient survival and tumor response.
Impact: Enabled early identification of ineffective therapies, minimizing patient exposure to toxicity and optimizing treatment selection.
References: Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

3.4 Organoid Immune Co-Culture Models for Cancer Vaccines

Discovery: Tumor organoids co-cultured with autologous peripheral blood lymphocytes simulated the tumor immune microenvironment (TIME), assessing individual responses to checkpoint inhibitors and CAR-T cell therapies.
Validation: Identified tumor-specific antigens with high immunogenicity, enabling the design of personalized cancer vaccines.
Impact: Revolutionized immunotherapy development by capturing spatial organization and immune dynamics.
References: From petri dish to patient care: organoids bring personalised cancer therapy closer

3.5 Kidney Assembloids for Polycystic Kidney Disease (PKD)

Discovery: Researchers generated the most complex kidney structures to date—assembloids combining filtering nephrons with urine-concentrating collecting ducts.
Validation: Assembloids recapitulated key features of PKD, including inflammation and fibrosis, previously irreproducible in animal models.
Impact: Opened new avenues for studying chronic kidney disease and predicting drug-induced nephrotoxicity.
References: Researchers develop most advanced kidney organoid yet for disease modeling and drug discovery

3.6 Miller-Dieker Syndrome (MDS) Root Cause

Discovery: Human brain organoids derived from MDS patient cells identified the root cause of Miller-Dieker Syndrome as early neural stem cell death and severe division defects in “outer radial glia”.
Validation: Time-lapse imaging of patient-derived organoids showed that these specific glia cells—which are entirely absent in mouse models—failed to divide properly.
Impact: Solves a long-standing mystery in rare neurodevelopmental disease that was impossible to investigate using traditional rodent models and proves that patient-derived organoids can bridge the gap between animal models and human pathophysiology.
References: An Organoid-Based Model of Cortical Development Identifies Non-Cell-Autonomous Defects in Wnt Signaling Contributing to Miller-Dieker Syndrome, Cerebral organoids expressing mutant actin genes reveal cellular mechanism underlying microcephaly

3.7 IGF-1 Dependency in Lung Cancer Subtypes

Discovery: A comprehensive library of 40 SCLC organoid lines revealed that non-neuroendocrine small cell lung cancer (SCLC) depends on the insulin-like growth factor 1 (IGF-1) signaling axis for growth.
Validation: Genetic ablation of TP53 and RB1 in human alveolar organoids replicated this dependency, and IGF1R inhibitors were shown to effectively suppress growth in patient-derived models.
Impact: Identifies IGF1R inhibition as a promising new therapeutic strategy for a specific, treatment-resistant patient population.
References: An organoid library unveils subtype-specific IGF-1 dependency via a YAP–AP1 axis in human small cell lung cancer

3.8 Intestinal Organoids Reveal Stem Cell Biology and Disease Mechanisms

Discovery: Developed the first human intestinal organoids from adult stem cells, enabling study of gut disease, cancer, and drug responses in human tissue.
Validation: Extended to liver, kidney, brain, and retinal organoids worldwide.
Impact: Foundational technology for human organoid research.
References: Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche

3.9 Brain Organoids Model Microcephaly Caused by Zika Virus

Discovery: Human brain organoids demonstrated Zika virus infection of neural progenitor cells, modeling microcephaly-like features in human tissue.
Validation: Human-specific features of microcephaly were captured by the organoids which mouse models had been unable to fully recapitulate.
Impact: Provided human-specific insights into Zika virus pathology.
References: [Qian et al., Cell 2016; Garcez et al., Science 2016] Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure, Zika virus tested in human brain organoids

4. In Silico Modeling, PBPK, and Computational Methods

In silico modeling—including Physiologically Based Pharmacokinetic (PBPK) models and digital twins—simulates drug behavior in the human body, enabling virtual clinical trials and predictive toxicology. By integrating computational methods with biological data, these approaches reduce reliance on animal testing, optimize dosing regimens, and accelerate the development of safe and effective therapies.

4.1 Physiologically Based Pharmacokinetic (PBPK) Modeling

Discovery: PBPK models integrate in vitro data on absorption, distribution, metabolism, and excretion (ADME) with physiological parameters to predict internal human exposure.
Validation: Correctly estimated systemic exposure of caffeine and coumarin in different product types, demonstrating that model-informed approaches can replace in vivo toxicokinetics.
Impact: Enabled virtual clinical trials and optimized dosing regimens without animal testing.
References: Advancing drug development with “Fit-for-Purpose” modeling informed approaches, SCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation, The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine, AI-driven virtual cell models in preclinical research, Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation

4.2 Bioequivalence Bridging for Tofacitinib

Discovery: Pharmacokinetic/pharmacodynamic (PK/PD see 4.1) modeling was used to bridge the immediate-release formulation of tofacitinib to a new extended-release version for ulcerative colitis.
Validation: The computational model successfully established bioequivalence, satisfying regulatory safety and efficacy requirements.
Impact: Supported FDA approval avoiding new Phase 3 clinical trials, significantly accelerating patient access to the new formulation.
References: Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form, Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects

4.3 Digital Twins for Clinical Trial Simulation

Discovery: Digital twins are virtual representations of individuals integrating clinical, genetic, and environmental data—promise to revolutionize clinical trial design.
Validation: Simulation of treatment strategies before patient enrollment, reducing risks and costs.
Impact: Could eliminate the need for many traditional clinical trials by predicting patient-specific responses.
References: Increasing acceptance of AI‐generated digital twins through clinical trial applications, The Use of Digital Healthcare Twins in Early-Phase Clinical Trials: Opportunities, Challenges, and Applications, Enhancing randomized clinical trials with digital twins, What are NAMs?

4.4 Quantitative Systems Pharmacology (QSP) Models

Discovery: QSP models combine mechanical simulations of physiology with molecular signaling pathways to predict immunogenicity and pharmacokinetics of complex biologics (e.g., monoclonal antibodies).
Validation: FDA highlighted QSP as a tool to reduce reliance on animal testing for “what-if” scenarios.
Impact: Accelerated the development of biologics and personalized medicine.
References: FDA animal testing phaseout urges AI-based trial alternatives, organoids, other “NAMs”, Beyond lab animals

4.5 AlphaFold Predicts Protein Structures

Discovery: AI-based prediction of protein 3D structures from amino acid sequences transformed structural biology and drug target identification supporting NAM workflows.
Validation: Open-access database covers over 200 million predicted structures with atomic accuracy even when similar architectures had not been previously discovered through animal research.
Impact: Provides data previously requiring years of laboratory work.
References: Highly accurate protein structure prediction with AlphaFold

5. High-Throughput & Omics-Based Approaches

High-throughput technologies such as CRISPR screens, single-cell RNA sequencing, and multi-omics integration enable rapid identification and validation of drug targets, disease mechanisms, and toxicity pathways. This section highlights how omics-based NAMs are reshaping mechanistic understanding and accelerating the discovery of novel therapies for diseases with high unmet medical needs.

5.1 Tox21 Consortium: High-Throughput Chemical Screening

Discovery: The Tox21 federal collaboration uses robotic high-throughput screening (HTS) to evaluate thousands of chemicals simultaneously, generating millions of data points on biological pathways, developing an 18-assay battery for the estrogen receptor (ER) pathway, identifying endocrine-disrupting compounds without animal testing.
Validation: EPA formally accepted this computational model as an alternative to traditional rodent assays.
Impact: Marked the first regulatory prioritization of robotically derived molecular data over animal testing.
References: Tox21: Chemical testing in the 21st century, United States Federal Government TOX21 Collaboration, About Tox21

5.2 Multi-Omics Integration for Toxicity Pathways

Discovery: Integrative NAMs combining genomics, transcriptomics, proteomics, and metabolomics revealed novel: Oxidative stress pathways, Mitochondrial dysfunction signatures, and Immune-modulating pathways.
Validation: Omics-based NAMs distinguished adaptive from adverse responses and generated candidate biomarkers for early detection.
Impact: Reshaped mechanistic understanding of chemical toxicity.
References: Multi-omics integration analysis, The future of pharmaceuticals: Artificial intelligence in drug discovery and development, Skin Sensitisation Case Study, Prospects and challenges of multi-omics data integration in toxicology

5.3 CRISPR Screens for Drug Target Validation

Discovery: CRISPR/Cas9 gene editing and single-cell RNA sequencing enabled rapid identification and validation of drug targets, verifying AI-predicted targets for cancer and neurodegenerative diseases.
Validation: Accelerated the discovery of novel treatments by linking gene perturbations to therapeutic efficacy.
Impact: Reduced reliance on animal models for target validation.
References: CRISPR Cas9 Gene Editing, CRISPR-Cas9 in Functional Genomics: Implications for Target Validation in Precision Oncology, Target Validation with CRISPR, The future of pharmaceuticals: Artificial intelligence in drug discovery and development

5.4 AOP-Linked In Vitro Screens for Seizure Liability

Discovery: A government-industry collaboration mapped mechanisms leading to drug-induced seizures using adverse outcome pathways (AOPs) and in vitro assays.
Validation: Identified 27 biological target families linked to seizure mechanisms and developed 100+ assay endpoints.
Impact: Enabled systematic, mechanism-focused screening for pro-convulsant risk early in development. Replaces animal models which fail to predict drug-induced seizures.
References: De-risking seizure liability, Can New Approach Methodologies De-Risk Drug Development?, iPSC derived cardiomyocytes for cardiac toxicity assessment

6. Toxicology & Safety Assessment via NAMs

NAMs are transforming toxicology and safety assessment by providing human-relevant models for predicting compound toxicity, skin sensitization, endocrine disruption, and mixture toxicology. This section explores how regulatory agencies and industries are adopting these methods to improve chemical risk assessment and reduce reliance on animal testing.

6.1 Endocrine Disruption Assessment (Tox21 ER Model)

Discovery: The Tox21 ER pathway battery identified compounds interfering with human hormones using robot-based results.
Validation: EPA accepted this computational model as an alternative to rodent uterotrophic assays.
Impact: Provides an accepted non-animal alternative for testing in hazard identification for endocrine disruptors.
References: Toxic Alerts of Endocrine Disruption Revealed by Explainable Artificial Intelligence, Tox21: Chemical testing in the 21st century, Use of New Approach Methodologies

6.2 Skin Sensitization Hazard & Potency Prediction

Discovery: The OECD TG 497 “Defined Approaches” guideline combined multiple NAMs specifically Peptide reactivity assays (DPRA), Keratinocyte activation (KeratinoSens), Dendritic-cell activation (h-CLAT), and In silico models.
Validation: Correctly classified skin sensitization hazard and potency for chemicals, including those not previously tested in animals, with performance equal to or better than mouse assays.
Impact: Established a regulatory framework for animal-free safety testing of skin sensitizers.
References: Skin Sensitisation Case Study: Comparison of Defined Approaches including OECD 497 Guidance, Advancing Skin Sensitization Potency Categorization Using U-SENS™ in OECD TG 497, Standardisation and international adoption of defined approaches for skin sensitisation, Evaluating the ability of defined approaches to predict the human skin sensitisation potential of chemicals previously untested in new approach methodologies, Case Study on the Use of Integrated Approaches for Testing and Assessment for skin sensitisation

6.3 Bioactivity-Exposure Ratio (BER) for PFAS Risk Assessment

Discovery: For emerging PFAS compounds, regulators used in vitro assays to calculate human equivalent doses (HED) and derive a Bioactivity-Exposure Ratio (BER).
Validation: BER served as a protective surrogate in the absence of traditional animal data.
Impact: Enabled risk-based prioritization of chemicals based on biological perturbation likelihood.
References: S13-02 NAMs to investigate chemical-induced immunotoxicity: the cases of PFAS and BPA analogs, [Use of new approach methods (NAMs) in risk assessment](https://www.canada.ca/en/health-canada/services/chemical-substances/fact-she ets/use-new-approach-methods-risk-assessment.html), Sensitivity Analysis of the Inputs for Bioactivity-Exposure Ratio Calculations in a NAM-Based Systemic Safety Toolbox

6.4 Mixture Toxicology via NAMs

Discovery: NAM-based defined approaches (originally for individual substances) were extended to complex mixtures (e.g., pesticide formulations).
Validation: Demonstrated that panels of in chemico, in vitro, and in silico assays could identify and rank sensitization potential of formulations.
Impact: Advanced the understanding of combined exposure effects without animal testing.
References: iPSC derived cardiomyocytes for cardiac toxicity assessment, Case Study on the Use of Integrated Approaches for Testing and Assessment for skin sensitisation of Diethanolamine, Chemical testing using new approach methodologies

6.5 Reconstructed Human Skin Models Replace Animal Testing for Cosmetics and Chemicals

Discovery: Validated by OECD and regulatory agencies as replacements for the Draize rabbit skin irritation test.
Validation: Developed by MatTek (EpiDerm), Episkin (L’Oréal), Henkel, now standard in the EU and increasingly adopted globally.
Impact: Eliminates animal use for skin irritation/corrosion endpoints for cosmetics and many chemicals in accepting jurisdictions.
References: In Vitro Skin Models as Non-Animal Methods for Dermal Drug Development and Safety Assessment, Artificial Skin Models for Animal-Free Testing

6.6 Corneal and Eye Irritation Models

Discovery: Validated alternatives to the Draize rabbit eye test.
Validation: Developed by EpiOcular (MatTek), SkinEthic HCE (Episkin), assesses eye irritation potential of chemicals and consumer products.
Impact: Provides human-relevant models for eye irritation testing with validated non-animal alternatives.
References: Tissue Engineered Mini-Cornea Model for Eye Irritation Test, Corneal epithelium models for safety assessment in drug development: Present and future directions

7. Regulatory & Industry Adoption of NAMs

Regulatory agencies and pharmaceutical companies are increasingly embracing NAMs to streamline drug development, enhance predictivity, and align with ethical and scientific advancements. This section examines key milestones—such as the FDA Modernization Act 2.0 and OECD standards—that are paving the way for the global adoption of human-relevant, animal-free methodologies in biomedical research.

7.1 FDA Modernization Act 2.0

Discovery: The FDA Modernization Act 2.0 (2022) removed the federal mandate for animal testing in new drug applications.
Validation: A significant move by FDA to move away from using the animal model.
Impact: Explicitly encouraged the use of NAMs (in vitro, in silico) in preclinical safety assessments.
References: FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches, How new approach methodologies are reshaping drug discovery, Organ-on-a-chip meets artificial intelligence in drug evaluation

7.2 FDA CDER NAM Validation Guidance (March 2026)

Discovery: FDA’s Center for Drug Evaluation and Research (CDER) released draft guidance establishing a validation framework for NAM-derived data.
Validation: Based on scientific confidence, human biological relevance, and “fit-for-purpose” utility, these guidelines are a significant move away from using the animal model.
Impact: Provided a clear regulatory pathway for integrating NAMs into Investigational New Drug (IND) applications.
References: FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development, New Approach Methodologies (NAMs) in Drug Development

7.3 OECD International Standards for NAMs

Discovery: The OECD Guidance Document 34 established international standards for the validation and acceptance of alternative test methods.
Impact: Facilitated global harmonization and adoption of NAMs in regulatory frameworks.
References: List of Alternative Test Methods and Strategies (or New Approach Methodologies NAMs), OECD Series On Testing And Assessment Number 34

7.4 Industry Investments in NAMs

Discovery: Major pharmaceutical companies (e.g., Roche, Johnson & Johnson, AstraZeneca) invested in NAMs: Emulate organ-on-a-chip platforms for toxicity prediction, Organoids and computational modeling for personalized medicine.
Validation: Business interests confirm the efficacy of NAMs.
Impact: Accelerated the transition toward human-relevant models in drug development.
References: How new approach methodologies are reshaping drug discovery

7.5 Tebentafusp (Kimmtrak) Regulatory Approval

Discovery: Tebentafusp (Kimmtrak) became the first immunotherapy to reach clinical trials and regulatory approval without in vivo animal pharmacodynamic data.
Validation: Because the drug lacked activity in any animal species, the sponsors relied entirely on human-centric NAMs to justify safety and efficacy for its IND submission.
Impact: Establishes a major regulatory milestone proving that human-relevant data can fully replace animal testing in specific contexts for first-in-class therapeutics.
References: Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma, Summary Basis of Decision for Kimmtrak in Canada

7.6 Aspect Biosystems — 3D Bioprinting Platform

Discovery: Developing bioprinted human tissue models as alternatives to animal testing, representing Canadian innovation in NAMs.
Validation: Bioprinted Tissue Therapeutics designed to replace biological function in the body.
Impact: Provides advanced tissue models for drug development.
References: Aspect Biosystems

7.7 Canadian Centre for Alternatives to Animal Methods (CCAAM)

Discovery: Canada’s first dedicated academic center for NAM research, conducted and promoted research using human-relevant, non-animal approaches.
Validation: Established in 2017 at the University of Windsor, Ontario.
Impact: Advances NAMs adoption in Canada.
References: CCAAM

7.8 USP Chapter <86> Recombinant Reagents for Endotoxin Testing

Discovery: The U.S. Pharmacopeia (USP) officially implemented Chapter <86> in May 2025, endorsing the use of non-animal-derived reagents for bacterial endotoxin testing.
Validation: The chapter allows the use of recombinant Factor C (rFC) and recombinant cascade (rCR) reagents, which utilize endpoint fluorescence and chromogenic techniques derived from gene sequences of the horseshoe crab.
Impact: Modernizes quality control in pharmaceutical manufacturing, potentially saving up to 90,000 animals per year while increasing batch-to-batch consistency.
References: <86> Bacterial Endotoxins Test Using Recombinant Reagents

Summary Table: Key NAM-Enabled Discoveries

Thematic Area	Discovery	Validation Status
AI-Driven Discovery	AI-designed drug for idiopathic pulmonary fibrosis (Insilico Medicine)	Phase II clinical trials
	AI repurposing of baricitinib for COVID-19	Clinical validation
	Topiramate identified for IBD via transcriptomic analysis	Preclinical/clinical studies
Organ-on-a-Chip	Liver-on-a-chip identifies hepatotoxicity in 87% of drugs missed by animal models	In vitro, regulatory acceptance
	Lung-on-a-chip for antiviral efficacy and tumor heterogeneity	In vitro, preclinical validation
	ALS Pathogenesis and Early Biomarkers	Multi-omics validation
	Cervical Protective Role in Dysbiosis	In vitro validation
Human Organoids	FIS assay for cystic fibrosis: personalized drug response prediction	Clinical implementation
	Patient-derived organoids for gene therapy in DMD	Preclinical validation
	OPTIC trial: 83.3% accuracy in predicting mCRC treatment response	Clinical validation
	Miller-Dieker Syndrome (MDS) Root Cause	Time-lapse imaging validation
	IGF-1 Dependency in Lung Cancer Subtypes	Genetic ablation validation
	Kidney assembloids for PKD modeling	In vitro validation
In Silico Modeling	PBPK modeling for drug safety and PK/PD predictions	FDA-accepted for submissions
High-Throughput & Omics	Tox21: 18-assay ER pathway battery for endocrine disruption	Regulatory acceptance (EPA)
	Multi-omics for toxicity pathway discovery	Peer-reviewed validation
Toxicology & Safety	OECD TG 497: Defined approaches for skin sensitization	Regulatory framework
	BER for PFAS risk assessment	Regulatory adoption
Regulatory Adoption	FDA Modernization Act 2.0: End of animal testing mandate in drug development	Legislative implementation
	FDA CDER NAM Validation Guidance (March 2026)	Draft guidance issued
	Tebentafusp (Kimmtrak) Regulatory Approval	Regulatory milestone

Conclusion: The NAMs Revolution in Biomedical Research

NAMs are not merely replacements for animal tests—they represent a fundamental transformation in scientific understanding and drug development. By leveraging human biology, robotics, AI, and computational modeling, NAMs offer:

Greater predictive accuracy for human responses.
Faster, cheaper, and more ethical research.
Personalized medicine through patient-specific models (organoids, organ-on-a-chip).
Regulatory acceptance and industry adoption.

The discoveries highlighted in this report demonstrate that NAMs are already delivering validated medical breakthroughs, from AI-designed drugs to organoid-based therapies and in silico clinical trials. As these technologies mature, they will redefine the future of biomedical research and patient care.

Suggested next steps for innovators:

Explore specific NAM platforms (e.g., Emulate, Insilico Medicine) for your research or project needs.
Investigate regulatory pathways for integrating NAMs into your workflow. See notebooklm whitepaper Strategic Framework for Navigating the Regulatory Transition to New Approach Methodologies (NAMs)
Consider collaborations with industry leaders in organ-on-a-chip or AI-driven drug discovery.